These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14687273)

  • 1. A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats.
    Sheridan SL; Pignone MP; Lewis CL
    J Gen Intern Med; 2003 Nov; 18(11):884-92. PubMed ID: 14687273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Numeracy and the medical student's ability to interpret data.
    Sheridan SL; Pignone M
    Eff Clin Pract; 2002; 5(1):35-40. PubMed ID: 11874195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of presenting risk information in different formats to cardiologists. A Latin American survey.
    Borracci RA; Piñeiro DJ; Arribalzaga EB
    Arch Cardiol Mex; 2015; 85(1):3-8. PubMed ID: 25450431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint and separate evaluation of risk reduction: impact on sensitivity to risk reduction magnitude in the context of 4 different risk information formats.
    Gyrd-Hansen D; Halvorsen P; Nexøe J; Nielsen J; Støvring H; Kristiansen I
    Med Decis Making; 2011; 31(1):E1-10. PubMed ID: 21173438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decisions on drug therapies by numbers needed to treat: a randomized trial.
    Halvorsen PA; Kristiansen IS
    Arch Intern Med; 2005 May; 165(10):1140-6. PubMed ID: 15911727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different ways to describe the benefits of risk-reducing treatments: a randomized trial.
    Halvorsen PA; Selmer R; Kristiansen IS
    Ann Intern Med; 2007 Jun; 146(12):848-56. PubMed ID: 17577004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Communicating effectiveness of intervention for chronic diseases: what single format can replace comprehensive information?
    Stovring H; Gyrd-Hansen D; Kristiansen IS; Nexoe J; Nielsen JB
    BMC Med Inform Decis Mak; 2008 Jun; 8():25. PubMed ID: 18565218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Communicating data about the benefits and harms of treatment: a randomized trial.
    Woloshin S; Schwartz LM
    Ann Intern Med; 2011 Jul; 155(2):87-96. PubMed ID: 21768582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Number Needed to Treat (NNT) as a Measure of Treatment Effect in Respiratory Medicine.
    Cazzola M
    Treat Respir Med; 2006; 5(2):79-84. PubMed ID: 16512688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The number needed to treat (NNT) and the number needed to harm (NNH)].
    Suter K; Briel M; Günther J
    Med Monatsschr Pharm; 2015 Mar; 38(3):103-6. PubMed ID: 26364396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating Relative Risk Changes with Baseline Risk: Presentation Format and Numeracy Matter.
    Bodemer N; Meder B; Gigerenzer G
    Med Decis Making; 2014 Jul; 34(5):615-26. PubMed ID: 24803429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis.
    Betts TR; Sadarmin PP; Tomlinson DR; Rajappan K; Wong KC; de Bono JP; Bashir Y
    Europace; 2013 Jun; 15(6):813-9. PubMed ID: 23365069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical doctors' perception of the "number needed to treat" (NNT). A survey of doctors' recommendations for two therapies with different NNT.
    Halvorsen PA; Kristiansen IS; Aasland OG; Førde OH
    Scand J Prim Health Care; 2003 Sep; 21(3):162-6. PubMed ID: 14531508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laypersons' understanding of relative risk reductions: randomised cross-sectional study.
    Sorensen L; Gyrd-Hansen D; Kristiansen IS; Nexøe J; Nielsen JB
    BMC Med Inform Decis Mak; 2008 Jul; 8():31. PubMed ID: 18631406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs.
    Sinsky CA; Foreman-Hoffman V; Cram P
    J Gen Intern Med; 2008 Feb; 23(2):164-8. PubMed ID: 18163191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The number needed to treat as a measure of effect in the treatment of primary immune thrombocytopenia].
    Vizcaíno G; Vizcaíno-Carruyo J
    Invest Clin; 2012 Mar; 53(1):16-27. PubMed ID: 22524105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of presenting absolute v. relative risk reduction in the elicitation of patient values for heart disease prevention with conjoint analysis.
    Griffith JM; Lewis CL; Hawley S; Sheridan SL; Pignone MP
    Med Decis Making; 2009; 29(2):167-74. PubMed ID: 19279298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerable variation in NNT - a study based on Monte Carlo simulations.
    Wisløff T; Aalen OO; Kristiansen IS
    J Clin Epidemiol; 2011 Apr; 64(4):444-50. PubMed ID: 20947294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Communicating Absolute Fracture Risk Reduction and the Acceptance of Treatment for Osteoporosis.
    Ralston KAP; Phillips J; Krause A; Hauser B; Ralston SH
    Calcif Tissue Int; 2022 Jun; 110(6):698-702. PubMed ID: 35152304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative risk, absolute risk and number needed to treat: basic concepts.
    Carneiro AV
    Rev Port Cardiol; 2009 Jan; 28(1):83-7. PubMed ID: 19388495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.